Basalog biosimilar insulin glargine: Completed Phase III enrollment

Mylan completed enrollment of 500 patients in the open-label Phase III INSTRIDE 1 trial comparing once-daily biosimilar insulin glargine plus Humalog insulin lispro vs. once-daily Lantus insulin gla...